



Sheet 1 of 4

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1748R1ESerial No.
10/088,950

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Frederic deSavauge et al.Filing Date
20 Mar 2002

Group

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
RKH	* 1	4,275,149	23.06.81	Litman et al.			
	* 2	4,816,567	28.03.89	Cabilly et al.			
	* 3	5,223,409	29.06.93	Ladner et al.			
	* 4	5,403,484	04.04.95	Ladner et al.			
	* 5	5,545,806	13.08.96	Lonberg et al.			
	* 6	5,545,807	13.08.96	Surani et al.			
	* 7	5,569,825	29.10.96	Lonberg et al.			
	* 8	5,571,698	05.11.96	Ladner et al.			
	* 9	5,625,126	29.04.97	Lonberg et al.			
	*10	5,633,425	27.05.97	Lonberg et al.			
	*11	5,658,570	19.08.97	Newman et al.			
	*12	5,681,722	28.10.97	Newman et al.			
	*13	5,693,780	02.12.97	Newman et al.			
	*14	5,750,105	12.05.98	Newman et al.			
	*15	5,750,373	12.05.98	Garrard et al.			
RKH	*16	5,756,096	26.05.98	Newman et al.			

RECEIVED
NOV 05 2002
TECH CENTER 1800/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
RKH	*17	WO 97/44455	27.11.97	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

RKH	*18	Altschul et al., "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs" <u>Nucleic Acids Research</u> , 25(17):3389-3402 (1997)
	*19	Bazan, J., "Structural Design and Molecular Evolution of a Cytokine Receptor Superfamily" <u>Proc. Natl. Acad. Sci. USA</u> 87:6934-6938 (1990)
	*20	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes" <u>The Journal of Immunology</u> 147(1):86-95 (1991)
	*21	Bolton, C., "Recent Advances in the Pharmacological Control of Experimental Allergic Encephalomyelitis (EAE) and the Implications for Multiple Sclerosis Treatment." <u>Multiple Sclerosis</u> , 1:143-149 (1995)
	*22	Carter et al., "Improved Oligonucleotide Site-Directed Mutagenesis Using M13 Vectors" <u>Nucl. Acids Res.</u> 13(12):4431-4443 (June 25, 1985)
	*23	Chambers and Allison., "Co-Stimulation in T Cell Responses." <u>Current Opinion in Immunology</u> , 9(3):396-404 (Jun 1997)
	*24	Clackson et al., "Making Antibody Fragments Using Phage Display Libraries" <u>Nature</u> 352:624-628 (1991)
RKH	*25	Cole et al., "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer" <u>Monoclonal Antibodies and Cancer Therapy</u> , New York:Alan R. Liss, Inc. pps. 77-96 (1985)

Examiner

Ronald K. Himmelfarb

Date Considered

3/7/05

*Examiner: Initial if reference considered whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1748R1ESerial No.
10/088,950LIST OF DISCLOSURES CITED BY APPLICANT
(Use several sheets if necessary)Applicant
Frederic deSavauge et al.Filing Date
20 Mar 2002

Group

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

RK1	*26	Constant, S.L. et al., "Induction of Th1 and Th2 CD4+ T Cell Responses: The alternative approaches" <u>Annual Review of Immunology</u> 15:297-322 (1997)
	*27	Cosman, D., "The Hematopoietin Receptor Superfamily" <u>Cytokine</u> 5(2):95-106 (Mar 1993)
	*28	Finn and Lotze., "Introduction: Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer." <u>Journal of Immunotherapy</u> , 21(2):114-118 (Mar 1998)
	*29	Fishwild et al., "High-Avidity Human IgGK Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice" <u>Nature Biotechnology</u> , 14(7):845-851 (Jul 1996)
	*30	Held et al., "Real time quantitative PCR" <u>Genome Research</u> 6(10):986-994 (1996)
	*31	Hoogenboom and Winter, "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V _H Gene Segments Rearranged in Vitro" <u>J. Mol. Biol.</u> 227:381-388 (1992)
	*32	Hsieh, C.S. et al., "Development of Th1 CD4+ T Cells Through IL-12 Produced by Listeria-Induced Macrophages" <u>Science</u> 260:547-549 (1993)
	*33	Jenkins, M., "The Ups and Downs of T Cell Costimulation." <u>Immunity</u> , 1(6):443-446 (Sep 1994)
	*34	Jones et al., "Replacing the Complementarity-Determining Regions in a Human Antibody with those from a Mouse" <u>Nature</u> 321:522-525 (May 29, 1986)
	*35	June et al., "The B7 and CD28 Receptor Families." <u>Immunology Today</u> , 15(7):321-331 (Jul 1994)
	*36	Kaplan, M. H. et al., "Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice" <u>Nature</u> 382:174-177 (1996)
	*37	Kohler, G. and Milstein, C., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity" <u>Nature</u> 256:495-497 (August 7, 1975)
	*38	Kuhn, R. et al., "Generation and analysis of interleukin-4 deficient mice" <u>Science</u> 254:707-710 (1991)
	*39	Kwon et al., "Manipulation of T Cell Costimulatory and Inhibitory Signals for Immunotherapy of Prostate Cancer." <u>Proc. Natl. Acad. Sci. USA</u> 94(15):8099-8103 (Jul 22, 1997)
	*40	Le Gros, G. et al., "Generation of Interleukin 4 (IL-4)-producing Cells In Vivo and In Vitro: IL-2 and IL-4 Are Required For In Vivo Generation of IL-4-producing Cells" <u>Journal of Experimental Medicine</u> 172:921-929 (1990)
	*41	Linsley and Ledbetter., "The Role of the CD28 Receptor During T Cell Responses to Antigen." <u>Annu. Rev. Immunol.</u> 11:191-212 (1993)
	*42	Lonberg and Huszar., "Human Antibodies From Transgenic Mice" <u>International Reviews of Immunology</u> 13(1):65-93 (1995)
	*43	Lonberg et al., "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications" <u>Nature</u> , 368(6474):856-859 (Apr 28, 1994)
	*44	Lynch et al., "Flt3 Ligand Induces Tumor Regression and Antitumor Immune Responses In Vivo." <u>Nature Medicine</u> , 3(6):625-631 (Jun 1997)
RK1	*45	Magram, J. et al., "IL-12-deficient mice are defective in IFN γ production and type 1 cytokine responses" <u>Immunity</u> 4:471-481 (1996)

Examiner

Rand K. Amis

Date Considered

3/7/05

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

NOV 05 2002

USCOMM-DC 80-398.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1748RIE

Serial No.

10/088,950

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Frederic deSavage et al.

Filing Date

20 Mar 2002

Group

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

RKM	*46	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling" <u>Bio/Technology</u> 10:779-783 (1992)
	*47	Marks et al., "By-Passing Immunization: Human Antibodies From V-gene Libraries Displayed On Phage" <u>J. Mol. Biol.</u> 222:581-597 (1991)
	*48	Melero et al., "Monoclonal Antibodies Against the 4-1BB T-cell Activation Molecule Eradicate Established Tumors." <u>Nature Medicine</u> 3(6):682-685 (Jun 1997)
	*49	Morrison, S., "Immunology: Success in Specification" <u>Nature</u> 368(6474):812-813 (Apr 28, 1994)
	*50	Neuberger, M., "Generating High-Avidity Human Mabs in Mice" <u>Nature Biotechnology</u> 14(7):826 (Jul 1996)
	*51	Noben-Trauth, N. et al., "An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice" <u>Proc. Natl. Acad. Sci. USA</u> 94:10838-10843 (1997)
	*52	O'Garra, A., "Cytokines induce the development of functionally heterogeneous T helper cell subsets" <u>Immunity</u> 8:275-283 (1998)
	*53	Presta, L., "Antibody Engineering" <u>Curr. Op. Struct. Biol.</u> 2:593-596 (1992)
	*54	Riechmann et al., "Reshaping Human Antibodies for Therapy" <u>Nature</u> 332:323-327 (Mar 24, 1988)
	*55	Romagnani, S. et al., "Human Th1 and Th2 cells: functional properties, mechanisms of development and role in diseases" <u>Allergologie</u> , Muenchen-Deisenhofen: D. Gustav Fischer Verlag Vol. 18(4):175-179 (1996)
	*56	Schwartz, R., "Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy." <u>Cell</u> 71(7):1065-1068 (Dec 24, 1992)
	*57	Seder, R.A. et al., "Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming" <u>Proc. Natl. Acad. Sci. USA</u> 90:10188-10192 (1993)
	*58	Shimoda, K. et al., "Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene" <u>Nature</u> 380:630-633 (1996)
	*59	Sprecher et al., "Cloning and Characterization of a Novel Class 1 Cytokine Receptor" <u>Biochem. & Biophys. Res. Comm.</u> 246:82-90 (1998)
	*60	Swain et al., "Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development" <u>Immunol. Rev.</u> 123:115-144 (1991)
	*61	Thimmappaya et al., "Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection" <u>Cell</u> 31(3 Pt 2):543-551 (Dec 1982)
	*62	Umetsu and DeKruyff, "Th1 and Th2 CD4+ Cells in the Pathogenesis of Allergic Diseases" <u>Soc. Exp. Biol. Med.</u> 215:11-20 (1997)
	*63	Urdal, D.L., "Cytokine Receptors" <u>Ann. Reports Med. Chem.</u> , Chapter 23, 26:221-228 (1991)
	*64	Wells et al., "Cassette Mutagenesis: An Efficient Method for Generation of Multiple Mutations at Defined Sites" <u>Gene</u> 34(2-3):315-323 (1985)
RKM	*65	Wells et al., "Importance of Hydrogen-Bond Formation in Stabilizing the Transition State of Subtilisin" <u>Philos. Trans. Royal Soc. London Ser. A</u> 317:415-423 (1986)

Examiner

Randy K. Himmels

Date Considered

3/4/08

NOV 05 2002

*Examiner: Initial if reference considered/whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
TECH CENTER 1600/2900
USCOMM-DC 80-398

U.S. Dept. of Commerce
Patent and Trademark Office

P1748R1E

10/088,950

Applicant

Frederic deSavauge et al.

Filing Date

20 Mar 2002

Group	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100
1	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

2.2.11

* 66

Wu, C. et al., "Characterization of IL-12 receptor $\beta 1$ chain (IL-12R $\beta 1$)-deficient mice" *J. Immunol.* 159:1658-1665 (1997)

RVM

* 67

Zoller and Smith., "Oligonucleotide-Directed Mutagenesis Using M13-Derived Vectors: An Efficient and General Procedure for the Production of Point Mutations in Any Fragment of DNA" Nucl. Acids Res. 10(20):6487-6500 (1982)

RECEIVED
NOV 05 2002
TECH CENTER 1600/2900

Examiner

Ramón E. Amador

Date Considered

3/7/08

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.